Management Team

Tarig Bashir



Tarig Bashir, PhD, joined FoRx Therapeutics as CEO in April 2021. He is a Pharma and Biotech Executive with over 15 years of experience and leadership in cancer drug discovery, translational oncology and external innovation. During his career, he has led and overseen discovery-stage and preclinical oncology portfolios, led strategic partnerships with pharma and academia, and contributed significantly to clinical compound development. Tarig held positions of increasing responsibility in Oncology R&D at Organon/Schering-Plough, Johnson & Johnson and Ipsen. Most recently he was Executive Vice President Discovery at Proteros, where his responsibilities included new company building.    

Read more

Tarig studied biology at the University of Würzburg and the State University of New York at Albany. He earned his PhD at the German Cancer Research Center (DKFZ) in Heidelberg and conducted his postdoctoral training at the New York University School of Medicine.

Thanos Halazonetis



Thanos Halazonetis holds a Dental Degree from the University of Athens and a PhD Degree in Genetics from Harvard University. He worked at Merck, Sharp & Dohme as a Research Fellow, before joining the faculty of the Wistar Institute and the University of Pennsylvania. In 2006, he joined the University of Geneva as Professor in the Department of Molecular Biology.

Read more

His research has always focused on cancer; after studying the p53 tumor suppressor and the responses of cells to DNA double-strand breaks, his research has focused on oncogene-induced DNA replication stress and the pathways by which cells repair collapsed DNA replication forks. He is an elected member of EMBO and of Academia Europaea.

Ulrich Lücking

PhD – Head of Chemistry


Ulrich Lücking, PhD, is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his path Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.

Read more

Prior to joining industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr,  and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.

Sotirios K. Sotiriou

PhD – Head of Biology


Sotirios Sotiriou, PhD, is a Molecular Cancer Biologist currently working as the Head of Biology at FoRx Therapeutics. Previously, he worked as a postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School, Broad Institute of MIT and Harvard and University of Geneva. Sotirios received his PhD degree with great distinction in Molecular Biology from the University of Geneva.

Read more

Sotirios completed his undergraduate studies in Biological Applications and Technology at the University of Ioannina. His research interests focus on DNA repair, DNA replication, and the mechanisms underlying genomic instability in human cancers.